A study in The Journal of Nuclear Medicine supported the safety, efficacy and dosimetry of [177Lu]Lu-AKIR001, a CD44v6-targeted radiotherapeutic. The research found high and selective tumor uptake, dose-dependent efficacy and a favorable safety profile, supporting a transition to first-in-human trials.

A Phase 2 study found that adding 177Lu-PNT2002 to stereotactic body radiotherapy improved progression-free survival in patients with oligorecurrent hormone-sensitive prostate cancer. The combination resulted in a median progression-free survival of 17.6 months, compared with 7.4 months with SBRT alone, with no increase in toxicity, researchers reported in the Journal of Clinical Oncology.

Researchers at the National Institutes for Quantum Science and Technology in Japan have developed a PET scanner that achieves a spatial resolution of sub-0.5 mm, surpassing previous limits. The new technology allows for detailed visualization of small brain structures in mice, aiding research into neurodegenerative disorders.

Researchers at the Australian Nuclear Science and Technology Organization have produced terbium-161 for the first time in Australia, using it for preclinical imaging experiments. Terbium-161 is a promising therapeutic radioisotope for personalized cancer treatment, particularly prostate cancer.

A study published in BJGP Open found that CT scans detected cancer in 13% of patients with nonspecific symptoms, even as referrals from general practitioners increased fivefold from 2012 to 2019. The retrospective cohort study included 729 patients and highlighted the importance of clinical judgment alongside imaging, as a normal CT scan does not completely rule out cancer.

A study in the Journal of the American College of Surgeons found a 40% reduction in missed radiation therapy sessions with a support program that addressed barriers such as transportation and disease management. The two-year "Breaking Barriers" program involved 194 institutions and led to a decrease in no-show rates at 71% of participating hospitals.

The deal to end the US government shutdown did not include an extension of enhanced Affordable Care Act subsidies, which are set to expire at the end of the year. Premiums for ACA marketplace plans have already risen in anticipation of the loss of enhanced subsidies, and some subscribers may see their premiums double or triple. Congress may act to extend the subsidies before the end of the year, but bipartisan support in the Senate and House approval would be required. Some subscribers may choose to forgo coverage if it is too expensive, or they may opt for a lower-tier plan, experts say.

A recent survey by HealthLink Dimensions reveals that while 40% of physicians are optimistic about the potential of AI in health care, 41% do not currently use any AI tools. The survey highlights that physicians view AI as an assistant rather than a replacement, with ChatGPT being the most popular tool among users. The findings suggest that AI tools that save time, reduce administrative burdens and maintain clinical autonomy are gaining traction among health care professionals.